Clinical Trial – Genetic Susceptibility to Bladder Cancer – Hypertension

High blood pressure (Hypertension) is extremely common and is a major cause of heart disease, kidney disease and stroke. Hypertension treatment within the UK is currently selected according to age and self-defined ethnicity (SDE). There are limitations to this approach which include wide variability in the response to hypertension drug classes between people. There is also uncertainty about selecting hypertension drugs for ethnic minorities other than those of African/Caribbean ancestry, for example, South Asians because of a lack of information from trials. In the AIM HY-INFORM study the investigators are looking to recruit equal number of black/caribbean, south asian and white european participants to be able to compare differences in hypertension treatments and ethnicity.

The primary objective of this study is to determine if the response to antihypertensive drugs differs by self defined ethnicity.

Study Type  : Interventional  (Clinical Trial)
Estimated Enrollment  : 1320 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme – AIMHY-INFORM)
Study Start Date  : November 2016
Estimated Primary Completion Date  : November 2020
Estimated Study Completion Date  : November 2021

 

Contacts
Contact: Gemma Bocking 01223 596377 [email protected]
Contact: Alicia Gore 01223 256599 [email protected]
ClinicalTrials.gov Identifier: NCT02847338  
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
+ Ask Questions